---
title: "Repatha (evolocumab) in cardiovascular event risk reduction: Guidelines questions"
description: "Guidelines questions on Repatha (evolocumab) in cardiovascular event risk reduction, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Repatha and LDL-C goals: what does the 2026 ACC/AHA guideline say? Repatha: when does the 2026 ACC/AHA guideline recommend adding a PCSK9 inhibitor? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/guidelines"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Repatha (evolocumab) in cardiovascular event risk reduction: Guidelines questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)

Questions that apply to every indication of Repatha are on [Repatha (evolocumab), all indications](https://www.evicenter.com/medical-information/repatha).

## Guidelines

<a id="repatha-guideline-ldl-goals"></a>

### Repatha and LDL-C goals: what does the 2026 ACC/AHA guideline say?

> “Goal: <70 mg/dL
>
> + ≥50% reduction from baseline
>
> Primary prevention adults at high risk (Prevent-ASCVD 10-year risk ≥10%)
> Adults with diabetes with multiple ASCVD risk factors
> Secondary prevention ASCVD patients NOT at very high risk”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=Goal%3A%20%3C70%20mg%2FdL,NOT%20at%20very%20high%20risk)

> “Goal: <55 mg/dL
>
> + ≥50% reduction from baseline
>
> Secondary prevention ASCVD patients at very high risk
> Patients with severe hypercholesterolemia with clinical ASCVD”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=Goal%3A%20%3C55%20mg%2FdL,severe%20hypercholesterolemia%20with%20clinical%20ASCVD)

Note: These are LDL-C goals by patient group from Amgen's summary of the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia (Blumenthal et al., JACC, published online March 2026) on the Repatha HCP site. They apply to LDL-C lowering therapy in general and do not name Repatha. Each list on the page ends in a See More control.

<a id="repatha-guideline-pcsk9i"></a>

### Repatha: when does the 2026 ACC/AHA guideline recommend adding a PCSK9 inhibitor?

> “The updated guideline outlines treatment sequencing with non-statin therapies, enabling earlier initiation of PCSK9i mAbs in select patient populations, including equal placement with ezetimibe*.”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=The%20updated%20guideline%20outlines%20treatment,including%20equal%20placement%20with%20ezetimibe%2A.)

> “*And in some cases, bempedoic acid”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=%2AAnd%20in%20some%20cases%2C%20bempedoic%20acid)

> “Adding a PCSK9i mAb is recommended to lower LDL-C as early as possible for patients with elevated Lp(a) and clinical ASCVD<sup>1</sup>”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=Adding%20a%20PCSK9i%20mAb%20is,with%20elevated%20Lp%28a%29%20and%20clinical)

> “When to Consider Adding a PCSK9i mAb for your patients with high LDL-C on maximally tolerated statin therapy<sup>1</sup>
> Adults with Diabetes Aged 40-75 with Multiple ASCVD risk factors
> Goal: LDL-C <70 mg/dL and ≥50% LDL-C reduction
> Consider adding a PCSK9i mAb, like evolocumab
> or ezetimibe
> Secondary ASCVD Prevention for Adults at Not Very High Risk
> Goal: LDL-C <70 mg/dL and ≥50% LDL-C reduction
> Optional Goal: LDL-C <55 mg/dL*
> Consider adding a PCSK9i mAb, like evolocumab
> or ezetimibe
> or bempedoic acid
> Secondary ASCVD Prevention For Adults at Very High Risk<sup>†</sup>
> Goal: LDL-C <55 mg/dL and ≥50% reduction
> Consider adding a PCSK9i mAb, like evolocumab
> and/or ezetimibe
> If goal still not achieved add bempedoic acid”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=When%20to%20Consider%20Adding%20a,not%20achieved%20add%20bempedoic%20acid)

> “*Based on clinical judgement and patient preference it is reasonable to treat patients with ASCVD not at very high risk to an LDL-C goal less than 55 mg/dL.
>
> <sup>†</sup>ASCVD at very high risk is defined as ≥2 major ASCVD events (ACS within the past 12 months, history of MI [other than recent ACS], history of ischemic stroke, symptomatic PAD) or with 1 major ASCVD event and ≥2 high-risk features (age ≥65 years, coronary bypass or percutaneous intervention, current smoker, diabetes, history of heart failure [HF], hypertension, LDL-C ≥100 mg/dL [2.6 mmol/L] despite maximally tolerated statin plus ezetimibe).”

Source: [REPATHA: PCSK9i mAbs in patients at increased CV risk | 2026 ACC/AHA/Multisociety Guideline, captured 2026-11-13](https://www.repathahcp.com/pcsk9i-mabs-in-ascvd#:~:text=%2ABased%20on%20clinical%20judgement%20and,maximally%20tolerated%20statin%20plus%20ezetimibe%29.)

Note: These are recommendations for PCSK9 inhibitor monoclonal antibodies (PCSK9i mAbs) as a class, in Amgen's summary of the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia (Blumenthal et al., JACC, published online March 2026) on the Repatha HCP site. The phrase "like evolocumab" and the description of the key updates are Amgen's wording.

## Related pages
- [Medical information: Repatha (evolocumab): Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)
- [Indication](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/dosing-and-administration)
